Microarray technologies have identified imbalances in the expression of specific genes and biological pathways in Alzheimer's disease (AD) brains. However, there is a lack of reproducibility across individual AD studies, and many related neurogenerative and mental health disorders exhibit similar perturbations. We are yet to identify robust transcriptomic changes specific to AD brains. This study meta-analysed publicly available brain-related disorders along with healthy cognitive individuals to decipher common and AD-specific brain transcriptomic changes.
INTRODUCTION
Alzheimer's disease (AD) is the most common form of dementia affecting over 44 million individuals worldwide, and numbers are expected to triple by 2050 [1] . The hallmark of the disease is characterised by the abnormal brain accumulation of amyloid-β (Aβ) protein and hyperphosphorylated tau filaments, which forms structures known as plaques and tangles respectively. The accumulation of these proteins contributes to the loss of connections between neurone synapses, leading to the loss of brain tissue and disruption of normal cognitive functions.
As AD progresses, the spread of plaques and tangles in the brain usually occurs in a predictable pattern and can begin up to 18 years prior to the onset of clinical symptoms [2] . In the earliest stages of the disease, plaques and tangles form in areas of the brain primarily involved in learning and memory, specifically the hippocampus and entorhinal cortex, both situated in the temporal lobe (TL) region [3] . Next, the frontal lobe (FL), a region involved in voluntary movement, is affected, followed by the parietal lobe (PL), a region involved in processing reading and writing. In the later stage of the disease, the occipital lobe, a region involved in processing information from the eyes, can become affected, followed by the cerebellum (CB), a region which receives information from the sensory systems and the spinal cord to regulates motor movement. Nerve cell death, tissue loss and atrophy occur throughout the brain as AD progresses, leading to the manifestation of clinical symptoms associated with loss of normal brain function. However, not all brain regions are neuropathologically affected in the same manner. The CB, which only accounts for 10% of the brain but contains over 50% of the brains total neurones, is often neglected in AD research because it is generally considered to be partially spared from the disease as plaques are only occasionally seen but tangles are generally not reported [4] [5] .
The histopathological spread of the disease is well documented, and with the advent of high throughput genomics approaches, we are now able to study the transcriptomic and biological pathways disrupted in AD brains. Microarrays can simultaneously examine thousands of genes, showing similar perturbations. We are yet to identify robust transcriptomic changes specific to AD brains.
In this study, we combined publicly available microarray gene expression data generated from AD human brain tissue and matched cognitively healthy controls to conduct the most extensive AD transcriptomic microarray meta-analyses known to date. We generate AD expression profiles across the temporal lobe, frontal lobe, parietal lobe and cerebellum brain regions. We further refine each expression profile by removing perturbations seen in other neurodegenerative and mental disorders (PD, BD, Schizophrenia [SCZ] , Major Depressive Disorder [MDD] and Huntington's Disease [HD]) to decipher specific transcriptomic changes occurring in human AD brains. These AD-specific brain changes may provide new insight and a better understanding of the disease mechanism, which in turn could provide new therapeutic targets for preventing and curing AD.
MATERIALS AND METHODS

Selection of publicly available microarray studies
Publicly available microarray gene expression data was sourced from the Accelerating Medicines For a study to be selected for inclusion, the data had to (1) be generated from a neurogenerative or mental health disorder, (2) be sampled from human brain tissue, (3) have gene expression measured on either the Affymetrix or Illumina microarray platform, (4) contain both diseased and suitably matched healthy controls in the same experimental batch and (5) contain at least 10 samples from both the diseased and control group.
Microarray gene expression data pre-processing
Data analysis was performed in RStudio (version 0.99.467) using R (version 3.2.2). All data analysis scripts used in this study are available at https://doi.org/10.5281/zenodo.823256. In brief, raw Affymetrix microarray gene expression data was "mas5" background corrected using R package "affy" (version 1.42.3) and raw Illumina microarray gene expression data Maximum Likelihood Estimation (MLE) background corrected using R package "MBCB" (version 1.18.0). Studies with samples extracted from multiple tissues were separated into tissue-specific matrices, log2 transformed and then Robust Spline Normalised (RSN) using R package "lumi" (version 2.16.0).
BRAAK staging is a measure of AD pathology and ranges from I-VI. In general, stages I-II, III-IV and V-VI represent the "low likelihood of AD", "probable AD" and "definite AD" respectively [30] . To maintain homogeneity within the sample groups and to be able to infer pathological related genetic changes, if BRAAK staging was available, clinical AD samples with BRAAK scores ≤ 3 or clinical control samples with BRAAK scores ≥ 3 were removed from further analysis.
Gender was predicted using the R package "massiR" (version 1.0.1) and used to subset the data into four groups based on diagnosis (case/control) and gender (male/female). Next, probes below the 90 th percentile of the log2 expression scale in over 80% of samples were deemed "not reliably detected" and were excluded from further analysis to eliminate noise [31] and increase power [32] .
Publicly available data is often accompanied by a lack of sample processing information, making it impossible to adjust for known systematic errors introduced when samples are processed in multiple batches, a term often known as "batch effects". To account for both known and latent variation, batch effects were estimated and removed using the Principal Component Analysis (PCA) and
Surrogate Variable Analysis (SVA) using the R package "sva" (version 3.10.0). Gender and diagnosis information were used as covariates in sva when correcting for batch effects. Outlying samples were iteratively identified and removed from each gender and diagnosis group using fundamental network concepts described in [33] . Platform-specific probe ID's were converted to Entrez Gene ID's using the BeadArray corresponding R annotation files ("hgu133plus2.db", "hgu133a.db", "hgu133b.db", "hugene10sttranscriptcluster.db", "illuminaHumanv4.db", "illuminaHumanv3.db") and differential expression analysis was performed using R package "limma" (version 3.20.9).
Finally, study compatibility analysis was investigated through the R package "MetaOmics" (version 0.1.13). This package uses differentially expressed genes (DEGs), co-expression and enriched biological pathways analysis to generate six quantified measures that are used to generate a PCA plot. The direction of each Quality Control (QC) measure is juxtaposed on top of the twodimensional PC subspace using arrows. Datasets in the negative region of the arrows were classed as outliers [34] and were removed from further analysis.
Meta-analysis
Datasets were grouped by the primary cerebral cortex lobes (TL, FL, PL) and the CB. Meta-analysis was performed using a "combining p-values" method known as "Adaptively Weighted with Onesided Correction" (AW.OC), implemented through the R package "MetaDE" (version 1.0.5) [34] . This method was chosen as it permits missing information across datasets which are introduced by combining data generated from different microarray platforms and expression chips. This avoids the need to subset individual datasets to common probes, which essentially allows for the maximum number of genes to be analysed. Furthermore, the method provides additional information on which dataset is contributing towards the meta-analysis p-value, and has been shown to be amongst the best performing meta-analysis methods for combining p-values for biological associations [35] . A gene was deemed significantly differentially expressed (DE) if the FDR adjusted meta p-value ≤ 0.05.
If a gene was significantly differentially expressed (DE) according to the meta-analysis, but at least one contributing datasets (according to AW.OC weights) had directional logFC discrepancies (i.e. upregulated in one dataset and down-regulated in another dataset), the gene was deemed to be discordant and was excluded from further analysis. This ensured we only captured robust, and consistently reproducible expression signatures.
The meta-analysis method does not provide an overall directional change for each gene; therefore, the standard error (SE) was calculated from the DE logFC values of each gene across the AW assigned significant datasets and used for standard meta-summary estimate analysis using the R package "rmeta" (version 2.16). This served as the meta logFC value in downstream analysis.
Generation of disease-specific meta-analysis expression profiles
Meta-analysis was performed across all AD datasets, followed by a separate meta-analysis across the non-AD disorder datasets. Using these meta-analysis results we generated three expression profiles;
(1) "AD expression profile", (2) "AD-specific expression profile" and (3) "common mental disorder expression profile".
The first expression profile, "AD expression profile", is a direct result of the meta-analysis performed on AD studies, which represents the changes typically observed from an AD and cognitively healthy control study design. The second expression profile, deemed as the "AD-specific expression profile", is produced by subtracting significantly DEG's found in the non-AD meta-analysis results from the "AD expression profile". This profile represents transcriptomic changes specifically observed in AD and not in any other neurogenerative or mental health disorder used in this study. The third expression profile, deemed as the "common mental disorder expression profile", represents genes which are significantly DE in all disorders used in this study, including AD.
Functional and gene set enrichment analysis
Gene set enrichment analysis (GSEA), and Gene Ontology (GO) analysis was conducted using an Over-Representation Analysis (ORA) implemented through the ConsensusPathDB web platform (version 32) [36] in May 2017. ConsensusPathDB incorporates numerous well-known biological pathway databases including BioCarta, KEGG, Reactome and Wikipathways. The platform performs a hypergeometric test while integrating a background gene list, which in this case is a list of all the genes that pass quality control in this study, compiles results from each database and corrects for multiple testing using the false discovery rate (FDR) [36] . A minimum overlap of the query signature and database was set to 2, and a result was deemed significant if the q-value was ≤ 0.05.
Network analysis
Protein-protein interaction (PPI) networks were created by uploading the meta-analysis DEG lists (referred to as seeds in network analysis) along with their meta logFC expression values to NetworkAnalyst's web-based platform http://www.networkanalyst.ca/faces/home.xhtml in June 2017. The "Zero-order Network" option was incorporated to allow only seed proteins directly interacting with each other, preventing the well-known "Hairball effect" and allowing for better visualisation and interpretation [37] . Sub-modules with a p-value ≤ 0.05 (based on the "InfoMap" algorithm [38] ) were considered significant key hubs, and the gene with the most connections within this hub was regarded as the key hub gene.
RESULTS
The AD microarray datasets
We Identified and acquired nine publicly available AD studies from ArrayExpress and AMP-AD, of which seven studies contained samples extracted from differing regions of the brain. The basic characteristics of each study and dataset are provided in Table 1 . Separating the nine studies by brain regions resulted in 46 datasets. Here a "dataset" is defined by brain region and study origin.
For example, ArrayExpress study E-GEOD-36980 consists of diseased and healthy samples extracted from three different tissues (temporal cortex, hippocampus and frontal cortex). All samples originating from the same tissue were classified as one dataset; therefore, study E-GEOD-36980 generated three datasets, representing the three different tissues.
The 46 AD datasets contained both AD samples and healthy controls, and were assayed using seven different expression chips over two different microarray platforms (Affymetrix and Illumina) and Nine publicly available AD studies were identified and acquired for this study. Separating the studies by tissue resulted in 46 datasets, each containing AD and healthy control samples. The brain tissue in each of the 46 datasets was mapped to their corresponding cerebral cortex (temporal lobe, frontal lobe or parietal lobe) or the cerebellum.
consisted of a total 2718 samples before QC. Briefly, the MetaOmics analysis identified study syn4552659 as an outlier and was therefore removed from further analysis (see supplementary text 1), resulting in 1501 samples (746 AD, 755 controls) in the remaining 22 datasets after QC
Summary of the AD meta-analysis DEG counts
The AD meta-analysis was performed on the 22 AD datasets and independently identified differentially expressed genes within the TL, FL, PL and CB brain regions. A summary of the number of datasets in each brain region and the number of significant DEG's identified is provided in Table 2 The complete DE results are provided in Supplementary Table 1 . Twenty-two AD datasets containing a total of 1501 samples remained in this study after QC. The case/control numbers represent the total number of AD/healthy controls subjects across all datasets within a particular brain region. The number of significant genes was identified through a combining p-value method known as Adaptively Weighted with One-sided Correction (AW.OC).
The non-AD disorder microarray datasets
Nine non-AD studies were identified and acquired, of which four studies consisted of samples generated from multiple disorders and brain regions. Separating the studies by disease and tissue equated to 21 datasets consisting of 8 SCZ, 6 BD, 4 HD, 2 MDD and 1 PD dataset with a total of 1166 samples after QC. The demographics of the non-AD datasets is provided in Table 3 Nine publicly available non-AD studies were identified and acquired. Separating the studies by tissue resulted in 21 datasets. Each dataset contained both diseased and complimentary healthy controls. The brain tissue in each of the 21 datasets was mapped to their corresponding cerebral cortex (temporal lobe, frontal lobe or parietal lobe) or the cerebellum.
Summary of non-AD brain disorder meta-analyses DEG counts
A second meta-analysis was performed on all non-AD disorders, and similarly to the AD metaanalysis, datasets were grouped into the TL, FL, PL and CB brain regions. An overview of the non-AD meta-analysis results are provided in Table 4 , and a complete list of DEG's is provided in Supplementary Table 2 . SCZ and BD were the only disorders with expression data available across all four brain regions and the frontal lobe brain region was the only region with expression data available from all non-AD disorders identified in this study. The The meta-analysis expression profiles
As described in the methods, three primary expression signatures were derived from the metaanalyses for each of the four brain regions: -1) "AD expression profile", 2) "AD-specific expression profile" and 3) "common mental disorder expression profile". The numbers of significant DEG's in each of the three expression signatures are provided in Table 5 . The DEG's from the "AD expression profile" in the TL brain region were not significantly DE in any other disorder included in this study. Hence, the "AD expression profile" and the "AD-specific expression profile" contained the same 323 genes for the TL brain region. The "AD-specific expression profile" for all four brain regions is provided in Supplementary Table 3 .
The "common mental disorder expression profile" within the four brain regions consisted of very little or no DEG's (except for the parietal lobe); hence, the downstream analysis did not yield any statistically significant results of biological relevance. We find little robust evidence of shared biology based on this data analysis and therefore, exclude all results generated from the "common mental disorder expression profile" from this paper; however, we provide the complete list of significantly DEG's within this profile in Supplementary Table 4 .
Common differentially expressed genes across multiple brain regions in AD
AD is known to affect all brain regions through the course of the disease, although not to the same degree, similar transcriptomic changes across all brain regions were deemed disease-specific, while perturbations in a single brain region were considered to be tissue-specific. We were particularly interested in disease-specific transcriptomic changes and therefore decided to focus on genes that were found to be consistently DE across multiple brain regions.
Meta-analysis of the AD datasets identified a total of 2494 unique genes as significantly DE. The distribution of these genes across the four brain regions is shown in Figure 1 . Forty-two genes were found to be perturbed across all four brain regions and can be grouped into three sets (Figure 2 ). The first group (Gene set 1) are expressed consistently in the same direction across all four brain regions and can be regarded as disease-specific. The second group (Gene set 2) are expressed in the same direction in the TL, FL and PL, but expression is reversed in the CB brain region, a region suggested to be spared from AD pathology [4] [5]. This expression pattern suggests these genes may be involved in AD pathology. Finally, the third group (Gene set 3) are inconsistently expressed across the four brain regions are most likely tissue-specific or even false-positives.
From the forty-two genes significantly differentially expressed across all brain regions, seven genes were DE in the same direction and belong to the "AD-specific expression profile", that is, these seven genes (down-regulated NDUFS5, SOD1, SPCS1 and up-regulated OGT, PURA, RERE, ZFP36L1) were consistently perturbed in all AD brain regions and not in any other brain region of any other mental disorder used in this study and can be considered unique to AD brains. The expression of these seven genes across AD brains is shown in Figure 3 .
Differentially expressed genes in brain regions affected by AD histopathology
In AD, the TL, FL and PL are known to be affected by both plaques and tangles, while the CB brain region is rarely reported to be affected. In addition to identifying genes DE across all brain regions and reversed in the CB brain region, we were also interested in genes perturbed in the TL, FL and PL and not the CB. These genes may also play a role in general AD histopathology and could be new therapeutic targets in preventing or curing AD.
Fifty-five genes were found to be significantly DE in TL, FL and PL but not the CB, of which seventeen were expressed in the same direction and were not DE in the other brain disorders used in this study. Nine of the seventeen genes (ATP1A1, ATP2A2, ATP6V1E1, GHITM, LDHA, NDRG4, NSF, RAB6A and RTN3) were consistently up-regulated, and eight genes (FDFT1, MT2A, NACC2, NFIB, RTN1, SH3GL2, SRRM2 and WAC) were consistently down-regulated in AD.
Furthermore, from the forty-two genes identified as significantly DE across all four AD brain regions, ten genes were in consensus in their expression across the TL, FL and PL brain region but expression is reversed in the cerebellum. Only 3 of these genes (UBA1, EIF4H and CLDND1) belong to the "ADspecific expression profile", and all three genes were significantly down-regulated in the TL, FL and PL, but significantly up-regulated in the CB brain region (see Gene set 2 in Figure 2 ).
"AD Expression Profile" functional gene set enrichment and GO analysis
Gene set enrichment analysis of the "AD expression profile" identified 205, 197, 98, and 45 biological pathways significantly enriched in the TL, FL, PL and CB brain regions respectively (Supplementary Table 5 ). There were ten pathways significantly enriched in all four brain regions, of which eight are involved in the "metabolism of protein" (specifically the translation process, the most significant being in CB brain region with a q-value=1.11e-7), one involved in "adenosine ribonucleotides de
Genes significantly differentially expressed in all regions of AD brains
Cerebellum Parietal Lobe Frontal Lobe Temporal Lobe novo biosynthesis" (TL q-value = 0.007, FL q-value = 7.56e-5, PL q-value = 0.04, CB q-value = 0.03) and one involved in the "digestive system" (TL q-value = 0.02, FL q-value = 0.02, PL q-value = 0.01, CB p-value = 0.02).
When excluding the CB brain region, 42 pathways were significantly enriched in the remaining three The biological GO analysis identified 384, 417, 216, and 72 biological components as significantly enriched in the TL, FL, PL and CB brain region respectively (Supplementary Table 6 ). There were 36
pathways significantly enriched across all four brain regions at a p-value threshold of ≤ 0.05 and nine at an FDR adjusted significant p-value threshold of ≤ 0.01. These nine processes are "cellular Excluding the CB brain region resulted in 84 common biological components being significantly enriched across the remaining three brain regions.
"AD-Specific Expression Profile" functional gene set enrichment and GO analysis
Analysis of the "AD-specific expression profile" identified 205, 196, 40 and 42 pathways as significantly enriched in the TL, FL, PL and CB brain region respectively in the GSEA analysis (Supplementary Table 7 ). The analysis identified six significantly enriched pathways across all four brain regions, and all are involved in "metabolism of protein" (specifically the translation process, with the most significant pathway being in the PL brain region with a q-value = 8.92e-7). The same six pathways were identified when the CB region was excluded.
The Supplementary Table 8 .
Network analysis hub gene identification
PPI networks were generated for each expression profile and in each of the four brain regions (TL, FL, PL and CB) to identify genes whose protein product interacts with other protein products from the same expression profile. Genes with more interactions than expected are referred to as hub genes and may be of biological significance. 
Temporal lobe hub genes
Frontal Lobe hub genes
The FL "AD expression profile" consisted of 460 DEG which represented 272 seed proteins and 620 edges. Two significant key hub genes were identified; up-regulated Amyloid Precursor Protein (APP, p-value = 1.98e-08) and down-regulated Heat Shock Protein 90-alpha (HSP90AA1, p-value = 0.003).
Using the "AD-specific expression profile" identified the same two key hub genes, with APP reaching a significant p-value of 2.11e-09.
Parietal Lobe hub genes
The PL "AD expression profile" consisted of 1736 DEG which represented 1437 seed proteins and 5720 edges. Similar to the TL and FL, two significant key hub genes were identified; down-regulated Cullin-3 (CUL3, p-value = 1.84e-10) and down-regulated UBC (p-value = 1.84e-10). Using the "ADspecific expression profile" (1023 DEGs, 810 seed proteins and 2351 edges) identified UBC as the only key hub gene, with a more significant p-value of 1.84e-10. The CUL3 gene is no longer a significant key hub gene in the network.
Cerebellum hub genes
The 
DISCUSSION
In this study, we acquired eighteen publicly available microarray gene expression studies covering six mental health disorders; AD, BD, HD, MDD, PD and SCZ. Data was generated on seven different expression BeadArrays and across two different microarray technologies (Affymetrix and Illumina).
The eighteen studies consisted of 3984 samples extracted from 22 unique brain regions which equated to 67 unique datasets when separating by disorder and tissue. However, due to study and sample outlier analysis, only 43 datasets (22 AD, 6 BD, 4 HD, 2 MDD, 1 PD and 8 SCZ) totalling 2,667 samples passed QC. We grouped the AD datasets by tissue, into the TL, FL, PL and CB brain regions to perform the largest microarray AD meta-analysis known to date to our knowledge, which identified 323, 460, 1736 and 867 significant DEG's respectively. Furthermore, we incorporated transcriptomic information from other mental disorders to subset the initial findings to 323, 435, 1023, and 828 significant DEG's that were specifically perturbed in the TL, FL, PL and CB brain regions respectively of AD subjects.
Genes specifically perturbed across AD brain regions
Seven genes (down-regulated NDUFS5, SOD1, SPCS1 and up-regulated OGT, PURA, RERE, ZFP36L1)
were DE in AD brains and not DE in the other disorders used in this study. We deemed these seven protein-coding genes as "AD-specific". Three of these genes (NDUFS5, SOD1 and OGT) have been previously associated with AD. Down-regulated NADH Dehydrogenase Ubiquinone Fe-S Protein 5
(NDUFS5) gene is part of the human mitochondrial respiratory chain complex; a process suggested to be disrupted in AD in multiple studies [38] [39] . A study investigating blood-based AD biomarkers identified 13 genes, including NDUFS5, which was capable of predicting AD with 66% accuracy (67% sensitivity and 75% specificity) in an independent cohort of 118 AD and 118 control subjects [41] .
The perturbation in NDUFS5 expression in the blood and brains of AD subjects suggests this gene may have potential as an AD biomarker and warrants further investigation.
Down-regulated Superoxide Dismutase 1 (SOD1) gene encodes for copper and zinc ion binding
proteins which contribute to the destruction of free superoxide radicals in the body and is also involved in the function of motor neurons [provided by RefSeq, Jul 2008]. Mutations in this gene have been heavily implicated as causes of familial amyotrophic lateral sclerosis (ALS) [42] and have also been associated with AD risk [43] . A recent study discovered SOD1 deficiency in an amyloid precursor protein-overexpressing mouse model accelerated Aβ oligomerisation and also caused Tau phosphorylation [44] . They also stated SOD1 isozymes were significantly decreased in human AD patients, and we can now confirm SOD1 is significantly under-expressed at the mRNA level in human AD brains as well.
The up-regulated O-Linked N-Acetyl Glucosamine Transferase (OGT) gene encodes for a glycosyltransferase that links N-acetylglucosamine to serine and threonine residues (O-GlcNAc). O-GlcNAcylation is the post-translational modification of O-GlcNAc and occurs on both neuronal tau and APP. Increased brain O-GlcNAcylation has been observed to protect against tau and amyloid-β peptide toxicity [45] . A mouse study has demonstrated a deletion of the encoding OGT gene causes an increase in tau phosphorylation [46] . In this study, we observe a significant increase in OGT gene expression throughout human AD brains, including the cerebellum where tangles are rarely reported, suggesting OGT gene is most likely not solely responsible for the formation of tangles.
OGT and O-GlcNAcase (OGA) enzymes facilitate O-GlcNAc cycling, and levels of GlcNAc have also been observed to be increased in the parietal lobe of AD brains [47] . Appropriately, OGA inhibitors have been tested for treating AD with promising preliminary results [48] , prompting further investigation into targeting OGT for AD treatment.
Genes involved in AD histopathology
The CB brain region is known to be free from tau pathology and occasionally free from plaques as well. We exploited the CB brain region as a secondary control to identify seventeen genes (ATP1A1, ATP2A2, ATP6V1E1, GHITM, LDHA, NDRG4, NSF, RAB6A, RTN3, FDFT1, MT2A, NACC2, NFIB, RTN1, SH3GL2, SRRM2 and WAC) DE specifically in TL, FL and PL and not the CB brain region of AD subjects.
From these genes, LDHA, RAB6A and RTN3 have been previously associated with AD. Lactate Dehydrogenase A (LDHA) gene encodes for a protein that catalyses the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis [provided by RefSeq, Sep 2008], a process previously suggested to be disrupted in AD brains [49] . RAB6A regulates the intracellular processing of the amyloid precursor protein (APP) [50] , and Reticulon 3 (RTN3) encodes for a protein that interacts and modulates the activity of beta-amyloid converting enzyme 1 (BACE1) and the production of amyloid-beta.
We identified an additional three AD-specific genes (UBA1, EIF4H and CLDND1) which were significant DE in all four brain regions. However, the genes were down-regulated in the TL FL and PL but up-regulated in the CB brain region. Ubiquitin-Like Modifier Activating Enzyme 1 (UBA1) encodes for a protein that catalyses the first step in ubiquitin conjugation to mark cellular proteins for degradation. Eukaryotic Translation Initiation Factor 4H (EIF4H) encodes for a translation initiation factors, which functions to stimulate the initiation of protein synthesis at the level of mRNA utilisation and Claudin Domain Containing 1 (CLDND1) is a transmembrane protein of tight junctions found on endothelial cells [51] . As the cerebellum is the only brain region spared from tangle formation and occasionally from plaque, we suggest these 20 genes could potentially be associated with AD histopathology.
Translation of proteins perturbed specifically in AD brains
Functional gene set enrichment analysis of the "AD expression profile" revealed more pathways were significantly perturbed in the TL, followed by the FL, PL and CB, which is the general route AD pathology is known to spread through the brain. We originally observed ten biological pathways being enriched across all AD brain regions, which included biological pathways likely to be irrelevant such as the "digestive system". However, when incorporating transcriptomic information from non-AD disorders, we were able to refine the AD expression signature to specific genes perturbed in AD only. This resulted in the enrichment of pathways only involved in the "metabolism of proteins", specifically the translation process which has been previously suggested in be associated with AD on numerous occasions [10] [11] [14] [15] [16] [17] . We now suggest this may be a biological process specifically disrupted in AD brains, and not BD, HD, MDD, PD or SCZ brains.
Previous biological perturbations observed in AD are only associated Temporal Lobe brain region.
Previous AD studies have consistently suggested the immune response [ [23] are disrupted in AD. We observe the same pathways enriched in our meta-analysis; however, only in the TL brain region, a brain region often heavily investigated in AD. Except for "metabolism of proteins", we did not observe any of these pathways significantly enriched across all of the four brain regions, suggesting these pathways observed to be perturbed in previous studies may be tissue-specific rather than diseasespecific.
Interspecies interactions possibly involved in AD
Gene Ontology analysis on the "AD expression profile" identified nine different biological components enriched across all four brain regions. However, when we remove genes perturbed in other mental disorders, we only observe four biological components as significantly enriched, and all four were indicative of interspecies interactions. AD brains have a prominent inflammatory component which is characteristic of infection, and many microbes have been implicated in AD, notably herpes simplex virus type 1 (HSV1), Chlamydia pneumonia, and several types of spirochaete [52] . Furthermore, Aβ has been suggested to be an antimicrobial peptide and has been shown to protect against fungal and bacterial infections [53] . Thus, the accumulation of Aβ may be part of the brains defence mechanism against infections. Although a controversial theory, we also observe a viral component in AD brains, and as a result of this meta-analysis, further suggest this maybe ADspecific and warrants further investigation.
Network analysis identifies AD-specific APP UBC and SUMO2 hub genes UPS has an immense impact on the amyloidogenic pathway of APP processing that generates Abeta [55] . A recent GWAS study identified UBC as a novel LOAD gene, and through network analysis also identified UBC as a key hub gene. The study validated their findings in a UBC C. elegans model to discover UBC knockout accelerated age-related AB toxicity [56] . We also observe the UBC gene being down-regulated and as a key hub gene in multiple regions of human AD brains, further providing evidence of its key role in AD.
Small Ubiquitin-Like Modifier 2 (SUMO2) gene encodes for a protein that binds to target proteins as part of a post-translational modification system, a process referred to as SUMOylation [57] .
However, unlike ubiquitin, which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability [provided by RefSeq, Jul 2008]. Early studies have indicated that the SUMO system is likely altered with AD-type pathology, which may impact Aβ levels and tau aggregation [57] . Genetic studies have supported this theory with a GWAS study linking SUMO-related genes to LOAD [58] ,
with further studies showing that the two natively unfolded proteins, tau and α-synuclein, are sumoylated in vitro [59] . We identified SUMO2 as a significant key hub gene in both the human TL and CB brain region. However, what makes this discovery interesting is that SUMO2 is significantly up-regulated in the TL, a region where both plaques and tangles can be observed, but significantly down-regulated in the CB, where only plaques have been occasionally observed, but tangles never reported. The up-regulation of SUMO2 gene may play a vital role in the formation of tangles, and further investigation into this gene is warranted.
Limitations
Although this study presents novel insights to AD-specific transcriptomic changes in the human brain, limitations to this study must be addressed. Firstly, we meta-analysed a total of 22 AD and 21
non-AD datasets, and many of these datasets lacked necessary experimental processing or basic phenotypic information such as technical batches, RNA integrity numbers (RIN), age, gender, or ethnicity, all of which can have confounding effects. To address this, we incorporated recommended best practices to estimate and correct for both known and hidden batch effects using SVA and COMBAT to ensure data is comparable between experiments and studies. However, this does not guarantee that all technical variation is completely removed.
Secondly, the terminology used to label brain tissue varied across studies, with some reporting a broad region such as the "hippocampus" used in study E-GEOD-48350, while others were very specific to the tissue layer, such as "hippocampus CA3" in study E-GEOD-29378. We, therefore, decided to map all brain tissue as mentioned in each dataset publication to their hierarchical cerebral cortex lobe (TL, FL and PL) and the CB. The mapping procedure was completed using publicly available literature defined knowledge, and we assume tissues within these brain regions are relatively comparable to infer AD-associated histopathological changes.
This study relied on publicly available transcriptomic data, and as previous research has heavily investigated brain regions known to be at the forefront of disease manifestation, this led to unbalanced datasets per brain region in both the AD and non-AD meta-analysis. Subsequently, the AD meta-analysis consisted of 14, 4, 2, and 2 datasets for the TL, FL, PL and CB brain regions respectively, with the PL brain region consisting of only 74 samples (28 AD and 46 controls) in total.
In addition, the non-AD meta-analysis lacked expression signatures form all non-AD diseases across all brain regions (except for FL). Nevertheless, the brain regions most affected by each disorder was captured in this study, suggesting we most likely were able to capture key brain transcriptomic changes relating to each disorder. Furthermore, as AD is known to affect all brain regions, albeit not to the same extent, we focus on transcriptomic changes observed across all brain regions that are also not observed in any brain region of the non-AD subjects, ensuring we capture transcriptomic signatures unique to AD brains.
Finally, we assume the non-AD datasets are comparable through meta-analysis, and by identifying common expression signatures that are not associated with individual disease mechanisms may represent false positives or even a general signature for "brain disorder". Removing this signature from the AD meta-analysis expression profile may result in transcriptomic changes specific to AD brains, revealing more relevant changes to the underlying disease mechanism rather than general mental diseases. Under this assumption, we observe more relevant and refined biological enrichment results. For example, we originally observed ten biological pathways enriched across all AD brain regions, including biological pathways such as the "digestive system". However, by refining the AD expression signature by removing genes perturbed in other related mental-disorders, only pathways involved in the "metabolism of proteins" remain, which has been previously suggested in be associated with AD on numerous occasions [10] [11] [14] [15] [16] [17] . This observation provides strong evidence of our assumption of incorporating non-AD diseases in this study to infer AD-specific changes as valid.
Conclusion
We present the most extensive human AD brain microarray transcriptomic meta-analysis study to date, incorporating, brain regions both affected and partially spared by AD pathology, and utilise related mental disorders to infer AD-specific brain changes. This led to the identification of seven genes specifically perturbed across all AD brain regions and are considered disease-specific, twenty genes specifically perturbed in AD brains which could play a role in AD neuropathology, and the refinement of GSEA and GO analysis results to identify specific biological pathways and components specific to AD. These AD-specific changes may provide new insights into the disease mechanisms, thus making a significant contribution towards understanding the disease and provides new therapeutic targets for the prevention and cure of AD.
